

1 **Manuscript Number** - Not allocated

2 **Keywords:** Implementation science, long acting injectables, antiretrovirals, gender equity, inclusion, HIV

3 **Title** – The ILANA study: a paradigm shift in ensuring equity of clinical implementation in HIV research

4 **Authors:**

5 Hamzah Z Farooq¹⁻³, Vanessa Apea¹⁻³, Bakita Kasadha⁴, Sadna Ullah¹⁻³, Gill Hilton-Smith⁵, Amber Haley

6 ⁵, Jenny Scherzer⁵, James Hand^{1,3}, Sara Papparini^{1,6}, Rachel Phillips⁷, Chloe Orkin¹⁻³

7 **Affiliations:**

8 ¹ SHARE Collaborative, Queen Mary University of London, London, UK

9 ² Blizard Institute, Queen Mary University of London, London, UK

10 ³ Department of Infection and Immunity, Barts Health NHS Trust, London, UK

11 ⁴ Nuffield Department of Primary Care Health Sciences, University of Oxford, Oxford, UK

12 ⁵ ViiV Healthcare, Middlesex, UK

13 ⁶ Wolfson Institute of Population Health, Queen Mary, University of London, London, UK

14 ⁷ Pragmatic Clinical Trials Unit, Centre for Evaluation & Methods, Wolfson Institute of Population Health

15 Queen Mary University of London, London, UK

16 **Corresponding Author:**

17 Professor Chloe M Orkin

18 Email - c.m.orkin@qmul.ac.uk

19 **Address:**

20 SHARE Collaborative,

21 Blizard Institute,

22 Queen Mary University of London,

23 4 Newark St,

24 London, E1 2AT,

25 UK

26

27 **Word Count:**

28 Abstract: 290

29 Text: 4000

30 **Ethical approval and consent to participate:**

31 Study was reviewed and approved by Research Ethics Committee and Health Research Authority.

32 Reference: 22/PR/0318

33 **Trial registration:**

34 Clinicaltrials.gov ref: NCT05294159

35 **Protocol version:**

36 1.8

37 **Consent for publication:**

38 All authors gave their consent for publication.

39 **Availability of data and materials:**

40 All the data for this study will be made available upon reasonable request to the corresponding author.

41 **Funding:**

42 ViiV Healthcare Ltd, research grant to Queen Mary University of London

43 **Conflict of interest COIS from each author**

44 CO has received research grants and honoraria from: ViiV Healthcare Ltd, GSK, GILEAD, MSD, Janssen &

45 Astrazeneca. SU has none to declare.

46 HZF has received travel grants and honoraria from: Janssen-Cilag; travel grants from GILEAD, ViiV

47 Healthcare Ltd, European Society of Clinical Virology, British HIV Association and the European AIDS

48 Clinical Society

49 None of the other authors have competing interests to declare in relation to this research.

50

51

52

53

54

55

56

57

58

59 **Abstract - 290/300**

60 *Introduction*

61 Cabotegravir and Rilpivirine (CAB+RPV-LA) is recommended as a treatment for HIV-1 allowing
62 people living with HIV to receive two-monthly injectable treatment, rather than daily pills. Providing
63 injectable therapy in a system designed to provide and manage patients on oral treatments poses
64 logistical challenges namely how resources are used to accommodate patient preference within
65 constrained health economies with capacity limitations. In this pragmatic multi-centre study, we aim
66 to understand the implementation of CAB-RPV-LA administration in two settings via mixed methods to
67 explore perspectives of participants and the clinical team delivering CAB+RPV-LA.

68 *Methods and Analysis*

69 Women, racially minoritised people and older people are chronically under-represented in HIV
70 clinical trials so the ILANA trial has set recruitment caps to ensure recruitment of 50% women, 50%
71 ethnically-diverse people and 30% over 50 years of age to include a more representative study
72 population. Utilising a mixed-methods approach, the primary objective is to identify and evaluate the
73 critical implementation strategies for CAB+RPV-LA in both hospital and community settings. Secondary
74 objectives include evaluating feasibility and acceptability of CAB+RPV-LA administration at UK clinics and
75 community settings from the perspective of HIV care providers, nurses, and representatives at
76 community sites, evaluating barriers to implementation, the utility of implementation strategies, and
77 adherence.

78 *Ethics and Dissemination*

79 Ethical approval has been obtained from the Health Research Authority Research Ethics Committee (REC
80 reference: 22/PR/0318).

81 The dissemination strategy has been formulated with the SHARE Collaborative Community Advisory
82 Board in order to maximise the impact of this work on clinical care and policy. This strategy draws upon
83 and leverages existing resources within the participating organisations, such as their academic
84 infrastructure, professional relationships and community networks fully. The strategy will particularly
85 harness the Public Engagement Team and press office to support dissemination of findings.

86 *Registration Number*

87 ClinicalTrials.gov Identifier: NCT05294159

88 **Strengths and Limitations of the Study**

89 1. This trial employs an anti-racist, anti-sexist, anti-ageist approach to protocol design, building
90 equitable recruitment into the fabric of the protocol.

91 2. This is the first implementation study to evaluate delivery of long-acting injectable HIV
92 antiretrovirals (LAIs) in both community and clinic settings and the first UK-based trial of LAI to
93 evaluate routine clinical practice within the National Health Service (NHS).

94 3. The trial also contains a mixed-methods sub-study exploring reasons for trial non-participation.

95 4. Trial sites are all large, urban centres. Further studies of implementation of LAIs in smaller and
96 rural settings will be needed.

97 5. The small sample size and specific targets for women and racially-minoritised groups aims to be
98 representative of people living with HIV in the UK, but may not be representative of all people
99 choosing the option of injectable medication.

101 **Main text (Word count: 4000/4000 - excluding headings)**

102 **Introduction**

103 HIV has been one of the greatest infectious challenges of our time. According to the World Health
104 Organization, 38-million people were living with HIV people living with HIV worldwide in 2019, 51% are
105 women and over 50% are racially-minoritised ⁽¹⁻³⁾. Anti-retroviral Therapy (ART) not only prevents
106 progressive, fatal illness but affords a near-normal life expectancy to people living with HIV who are
107 treated early ⁽⁴⁾. However, for those who find oral therapy difficult or impossible to take, it remains a
108 fatal illness.

109 Many studies have demonstrated demand and interest in long-acting therapies in people living with
110 HIV and are regarded as a welcome development by many ⁽⁵⁻⁷⁾. Long-acting injectable Cabotegravir and
111 Rilpivirine (CAB+RPV-LA) has been shown to be effective and safe as a complete regimen delivered
112 either monthly or two-monthly in three large phase III clinical trials ⁽⁵⁻⁷⁾. Participants on CAB+RPV-LA
113 overwhelmingly preferred it to daily oral therapy and had statistically significantly higher satisfaction
114 and acceptance scores according to validated patient reported outcome measures ⁽⁸⁾. CAB+RPV-LA
115 therapy has been shown to be highly acceptable^{9,10} and removes the burden of daily oral therapy for
116 people living with HIV . This can contribute to achieving viral suppression for those who, for multiple
117 complex reasons, can't or won't take oral therapy.

118 Current HIV clinical services in the UK are designed to provide care to people on oral therapy who are
119 generally monitored six-monthly. Providing injectable therapy within this resource-limited system poses
120 logistical challenges, namely how resources are used to accommodate anticipated patient preference
121 for long-acting treatment ⁽⁹⁾ . Common challenges to implementation (such as prioritization of patient
122 populations for preferred use, clinic infrastructure requirements, steady supply chains, provider and

123 patient training) require conducting rigorous implementation science research to ensure this treatment
124 reaches patients who would most benefit from it ⁽¹⁰⁾.

125 The NHS provides free ARTs to all, regardless of immigration status. CAB+RPV-LA is particularly
126 important for those who experience pill fatigue, HIV-related stigma and have fears of inadvertent
127 disclosure. This is highly relevant to the ethnically diverse population of people living with HIV in the
128 UK, many of whom come from marginalised and minoritised communities in which HIV-related stigma is
129 common and treatment outcomes are the poorest ⁽¹¹⁾.

130 Women, racially-minoritised people and older people are chronically under-represented in HIV clinical
131 trials ^(12, 13), yet disproportionately affected by HIV ^(12, 14). Fifty-one percent of people living with HIV
132 are women ⁽¹⁵⁾. Fifty-seven percent of heterosexuals people living with HIV in the UK are of Black
133 African heritage ⁽¹⁶⁾ and 14% of men-who-have-sex-with men (MSM) living with HIV are from racially-
134 minoritised backgrounds ⁽¹⁶⁾.

135 Achieving equity of care for women and racially-minoritised people living with HIV requires a bold and
136 inclusive approach to research ⁽¹⁷⁾ which is why we have developed this protocol for implementing LAIs
137 in multiple settings, with a focus on under-represented populations. The ILANA study aims at exploring
138 patients' experiences and perceptions of the long-acting injectable CAB+RPV and its facilitation in the
139 NHS. An anti-racist, anti-sexist, anti-ageist approach to recruitment is written into the protocol and
140 stipulates that male participants and White participants will be capped at 50%, with a cap at 70% for
141 patients younger than 50 years of age.

142 In this pragmatic real-world trial, LA CAB+RPV will be delivered in the clinics for the first six-months and
143 each site will identify the most pragmatic community setting in which to deliver CAB+RPV-LA during the
144 second six-months as an additional option alongside those who choose to continue receiving care in

145 hospital clinics. Consequently, this study explores implementation of a standard-of-care treatment in
146 two types of setting. The study includes a mixed-methods sub-study (NO-LANA) exploring reasons for
147 non-participation in individuals who opted not to take part in the main ILANA study.

148 **Aims and objectives**

149 This research aims to understand the implementation of CAB-RPV-LA administration in two settings –
150 the HIV clinic and in the community (eg, pharmacy, home, community organisation), via a mixed
151 methods approach exploring perspectives of participants and the clinical team delivering CAB+RPV-LA in
152 both settings.

153 The objectives are as follows:

154 **Primary objective:**

- 155 • To evaluate feasibility of CAB+RPV-LA administration at NHS HIV clinics and community settings in
156 people living with HIV who will receive CAB+RPV as part of their routine clinical care.

157 **Secondary objectives:**

- 158 1. To evaluate the feasibility and acceptability of CAB+RPV-LA administration at six clinics and
159 community settings in England for HIV care providers, and nurses
- 160 2. To evaluate the utility of and fidelity to Facilitation Calls and Blueprints (Standard Operating
161 Procedure) for the Community Nurse or Clinic Nurse
- 162 3. To describe barriers and facilitators to implementation of CAB+RPV-LA from the perspective of HIV
163 clinic staff, Community Nurses, Clinic Nurses and participants living with HIV
- 164 4. Describe the preferences of people living with HIV for the setting they receive injections and
165 reasons for their choice
- 166 5. Describe any change in treatment satisfaction scores and tolerability and acceptance of injections,
167 over time and by setting
- 168 6. To describe adherence to the dosing window

169 **Tertiary objectives**

- 170 • To describe proportion virologically suppressed (HIV viral load < 50 c/ML) and the safety of
171 CAB+RPV-LA
- 172 • To understand reasons for non-participation in the study

173 **Research questions**

- 174 • What are the experiences and perceptions of patients and healthcare-providers of the
175 acceptability, feasibility, safety, effectiveness, and tolerability of CAB+RPV-LA administration at
176 NHS HIV clinics and community sites?
- 177 • What are the unmet needs of patients taking CAB+RPV-LA as part of their future routine clinical
178 care?

- 179 • What are the characteristics and reasons of people living with HIV who are eligible but decline
180 to take part in the ILANA trial?

181 **Methods and Analysis**

182 *Study design*

183 This is a 12-month, multi-centre mixed-methods study examining the implementation of CAB+RPV-LA
184 injections in clinics and community-based settings in England in people who will receive CAB+RPV-LA as
185 part of their routine care.

186 **Study Setting:**

187 The study will take place at six NHS England HIV clinic sites: four in London (Barts Health NHS Trust,
188 Chelsea and Westminster Hospital NHS Foundation Trust, Guy's and St Thomas' NHS Foundation Trust,
189 Royal Free London NHS Foundation Trust), one in Liverpool and one in Brighton (Royal Liverpool
190 University Hospital and Royal Sussex County Hospital).

191 The study has two phases (Figure 1):

- 192 1. **Phase 1 (Clinic Phase)** - implementation of CAB+RPV-LA in the clinic with evaluation and
193 blueprint (Standard Operating Procedure) development.
- 194 2. **Phase 2 (Community/Hospital Phase)**- implementation of CAB+RPV-LA in the clinic and
195 community setting with evaluation and blueprint (SOP) development.

196 All participants begin injections in the clinic setting in Phase 1. During Phase 1, participants are screened
197 and consented to participate. Potential participants will be asked to indicate their preferred location for
198 Phase 2 (community or hospital site) and the reason for their preference. In Phase 2, participants will
199 either continue to receive injections in clinic or at community sites (e.g. home, community organization,

200 primary care). Each site has a target of 18-participants and agreed to adhere to recruitment caps to
201 ensure recruitment of at least 50% women, 50% racially-minoritised people, 30% people over the age of
202 50 are enrolled.

203 *Outcome Measures*

204 The study includes (i) participant outcomes; (ii) care provider and nurse participant outcomes; and (iii)
205 community site representative outcomes (described in table 1).

206 ***NO-LANA Sub-study***

207 Those who decline to take part in the ILANA study are a group of individuals otherwise willing to
208 commence on long-acting ART. Their reasons for declining are unlikely to relate to concerns about
209 starting a new regimen. This makes ILANA 'non-participants' an ideal group to explore the reasons why
210 individuals do not wish to take part in research. A sub-study, called NO-LANA, will be carried out
211 alongside ILANA in the same six study sites. It is a mixed-methods study based on an online survey and
212 individual interviews with people living with HIV who declined to take part in ILANA.

213 **Patient and public involvement and engagement**

214 The need for the ILANA study emerged from clinical practice and discussions with service users,
215 advocacy groups and healthcare professionals. Real world insights into the implementation of CAB+RPV-
216 LA surfaced as a cross-cutting priority for the groups.

217 To create a platform to deliver the meaningful inclusion and authentic co-production of research, the
218 research collaborative group (the SHARE Collaborative) have convened a paid community advisory
219 board. Through an iterative process of consultation, review and implementation, the community
220 advisory board are lending their living and lived experiences of HIV and their community expertise to

221 this and other projects at every step, from study design to data collection and knowledge translation. A
222 peer-researcher with lived experience of HIV is employed as an integral member of the research team
223 and is a named collaborator, contributing to the development of the protocol and questionnaires ⁽¹⁸⁾,
224 and will continue to contribute to delivery and meet ICJME criteria for authorship ⁽¹⁹⁾ .

225 **Recruitment**

226 Sites were selected based on research experience and on willingness to agree to a proactive recruitment
227 strategy with the application of caps. Weekly reporting is distributed via a newsletter to all sites with a
228 detailed breakdown of age, gender and ethnicity of participants recruited and uses forecasting to
229 monitor recruitment. If a site is unable to achieve the diversity targets, competitive recruitment will be
230 applied. The peer researcher will ask local community groups to discuss the trial within their
231 communities.

232 *Sample size*

233 One hundred and eight virologically suppressed people living with HIV will be included in this study and
234 will receive CAB+RPV-LA in the clinic and/or the community. There is no formal statistical comparison
235 between groups. The NO-LANA sub-study has no set sample size as all participants who declined to take
236 part in ILANA are eligible; it is estimated around 70 people will take part in NO-LANA.

237 *Participant identification*

238 Potential participants who will be receiving CAB+RPV-LA within their routine clinical care will be referred
239 to the study team by their clinic doctors within the HIV clinics of the six sites. The local HIV teams will
240 inform participants of the trial and will provide patient information leaflets with contact details of the
241 study team. Community organisations will inform their service users of the trial and trial sites. Local HIV
242 teams will inform potential NO-LANA sub-study participants no sooner than one-month after they have

243 been asked (and declined) to take part in ILANA that they are invited to take part in an anonymous
244 survey and individual interviews.

245 *Inclusion and exclusion criteria*

246 Adult people living with HIV (age \geq 18 years) will be invited to participate if they have capacity to
247 consent with the following criteria:

- 248 • Will receive CAB+RPV-LA as part of their routine clinical care
- 249 • In accordance with UK SmPC and NICE guidance:
 - 250 • Virologically suppressed (HIV-1 RNA <50 copies/ml) on a stable antiretroviral regimen
 - 251 • Without present or past evidence of viral resistance to, and no prior virological failure with
 - 252 agents of the non-nucleoside reverse transcriptase inhibitor (NNRTI) and integrase inhibitor (INI)
 - 253 class
 - 254 • Not co-infected with Hepatitis B
 - 255 • Pregnancy – participants of child-bearing age will be advised as per routine clinical care that
 - 256 there are insufficient data to recommend the use of the drug in pregnancy but will not be
 - 257 expected to use contraception (ie as per SmPC license)

258 Participants who have previously taken NNRTIs will be assessed to ensure no previous viral resistance
259 during the pre-screening process.

260 For the NO-LANA sub-study, anyone eligible for ILANA who declined the study is eligible.

261 **Data collection**

262 All participating sites will be assessed using a mixed-methods approach including questionnaires, semi-
263 structured qualitative interviews, templated data collection instruments and primary data sources (clinic
264 records). Clinical endpoints are tertiary and descriptive.

265 *Questionnaires*

266 Questionnaires use established instruments and some tailored to the purpose of the study. Patient
267 reported outcome measures such as the HIV treatment Satisfaction questionnaire will be used for
268 participant data collection, and the AIM (Acceptability of Intervention Measure), IAM (Intervention
269 Appropriateness Measure) and FIM (Feasibility of Intervention Measure) ⁽²⁰⁾ will be adapted and
270 anchored for implementation intervention. The NO-LANA sub-study questionnaire consists of a brief set
271 of demographic questions and questions about reasons for non-participation in ILANA.

272 *Participant questionnaires*

273 Questionnaires will be provided to participants at baseline, months one, four and twelve by clinicians
274 involved in the study, during their scheduled clinic visit.

275 *Provider questionnaires*

276 Community nurses and clinic nurses will complete questionnaires at baseline, and months four and
277 twelve. Community representatives will complete questionnaires at months eight and twelve.

278 *In-depth semi-structured interviews*

279 Non-probability purposive sampling will be used to recruit a diverse group of patients in terms of age,
280 gender, socioeconomic status as participants in qualitative interviews.

281 Interviews aim to elicit narratives about specific experiences, fears, hopes, concerns and unexpected
282 outcomes of utilizing CAB+RPV-LA . All interviews will be conducted by researchers trained in qualitative

283 interview methodology and implementation science frameworks, guided by a semi-structured interview
284 guide.

285 Interviews will be audio recorded and transcribed in full and are expected to last around 30 minutes.

286 Two interviews with people living with HIV will be conducted per clinic site at baseline and at M12.

287 Interviews will cease when data ‘saturation’ is reached – this is commonly defined as the point at which
288 collecting or observing more data will not lead to discovery of more information related to the research
289 questions.

290 The study team will also approach two-four HCP participants (doctors, nurses, and non-clinical staff
291 involved in the implementation and administration of CAB+RPV-LA) to take part in interviews, inform
292 them about the objectives of the study, its benefits, and risks, and how long the interview will take. The
293 interviews will take place at baseline and month twelve, with consent.

294 *NO-LANA sub-study*

295 All those who were invited to be part in ILANA, and declined, will be asked whether they wish to take
296 part in NO-LANA. If they agree, they will be sent a link to an online survey. The survey (the NO-LANA
297 Survey) will be anonymous and include: study information and consent and data protection information;
298 a set of questions on demographic characteristics; a set of questions asking for reasons why participants
299 did not want to take part in ILANA.

300 On completion of the survey there will be an option to leave contact details to take part in an individual
301 interview with a member of the research team to explore issues in more detail. Participants will receive
302 an information sheet (with option of receiving this via the clinic, email or post) and will have the option
303 of conducting the interview in the clinic, via phone, or video-call.

304 The one-to-one interviews will be semi-structured and designed to take around 30-mins to complete
305 (although longer time will be allocated) in recognition of the evidence that time pressures might be
306 amongst the reasons for non-participation. During the interview, participants will be asked to discuss, in
307 the first instance, their main reasons for not taking part in the ILANA trial. This will be followed by a set
308 of broader questions covering issues such as researchers' communication, delivery, modality and asking
309 participants for suggestions or preferences on how these might be improved in the future.

310 **Data analysis**

311 *Qualitative analysis*

312 Qualitative interviews will be audio-recorded, transcribed and coded. Thematic analysis will be adopted
313 to give in-depth understanding of the data generated. Data will be transferred into NVivo for analysis
314 using a mixture of inductive and deductive coding to explore and 'plot' reasons for non-participation.
315 NO-LANA sub-study participants' suggestions on improving recruitment strategies will be mapped and
316 summarised in a set of recommendations alongside the ILANA research findings.

317 *Quantitative analysis*

318 All participants who passed screening and entered the study (i.e., completed baseline eCRF) will be
319 included in the analysis population. Participants will be included in the analysis for each outcome if they
320 (i) are part of the analysis population (defined above); and (ii) have recorded data for the outcome of
321 interest (i.e., participants with missing outcome measures will be excluded). All data will be analysed
322 using Stata version 17 or later (StataCorp, College Station, TX, USA). A detailed statistical analysis
323 describing the full analyses is available in Appendix A.

324 *Participant flow and baseline characteristics*

325 A Consolidated Standards of Reporting Trials (CONSORT) diagram will be constructed to describe
326 participant flow through the ILANA study. Baseline characteristics will be summarised descriptively and
327 will be presented by location (clinic or community) and overall. NO-LANA sub-study survey data will be
328 analysed to produce descriptive statistics about demographic characteristics of non-participants.

329 *Analysis of primary and secondary outcomes*

330 The analysis of the primary, secondary and tertiary (including safety) outcomes will be descriptive.
331 Summary statistics will be provided for each outcome (mean (SD) or median (IQR), or number (percent)),
332 depending on the type of outcome. For each outcome, we will summarise the number (%) of
333 participants with available outcome data (the number included in the analysis, and conversely the
334 number with missing outcome data and thus excluded from the analysis).

335 *Subgroup analyses*

336 Subgroup analyses will be performed to investigate whether predefined outcome measures vary across
337 healthcare setting (clinic/community) and participant characteristics: gender (man/woman/non-binary)
338 and ethnicity (Black-African, Black-Caribbean, Black-British, Asian, White, Mixed Race, Other). Full details
339 of the subgroup analyses to be performed can be found in appendix A.

340 **Ethics and dissemination**

341 *Ethical considerations*

342 All participants will be receiving CAB+RPV-LA as part of their routine care, regardless of the study. Any
343 patient who does not wish to participate in this study, will still receive the treatment if they wish as part
344 of their routine care.

345 Members of the healthcare team will seek verbal consent from potential participants to contact them
346 with further study information. Once participants have verbally agreed to participate in an eligibility
347 screening or to receive further information about the study, the informed consent process will begin.
348 Prior to interviews, the researcher will again seek verbal consent. Ethical approval has been obtained
349 from the Health Research Authority Research Ethics Committee (REC reference: 22/PR/0318).

350 *Data protection and patient confidentiality*

351 Data protection has been central to the design. Data minimisation will be practised, with minimal
352 personally identifiable information collected only when necessary. We will ensure an Information-
353 governance tool-kit, GDPR and data-protection act compliant, robust, data-management policy and
354 infrastructure. Data access will be restricted through a secure user-credentialing process.

355 Personal data collected for this project will include consent forms, medical data, questionnaires,
356 recorded interviews, transcribed interviews and a digital key linking research participants to a unique
357 code number (pseudoanonymisation code). This data will be transferred and stored securely within the
358 QMUL data safe haven.

359 In the event that any hard copies of signed consent forms or of questionnaire are required, these will be
360 stored in locked filing cabinets in an area with restricted access.

361 Interview audio files will be recorded on password-protected encrypted digital voice recorders and
362 deleted from the from the digital voice recorder once directly uploaded onto encrypted hard drives.
363 Audio-recordings will be assigned to the relevant unique study number and destroyed once they have
364 been transcribed and checked. Hard copies of pseudonaymised transcripts will be stored in locked filing
365 cabinets and on restricted-access, password-protected on QMUL safe haven.

366 For the NO-LANA sub-study survey, any contact detail provided to be contacted for further individual
367 interviews will be collected in a separate survey page so details cannot be linked to the anonymous
368 survey data.

369 **Output and dissemination**

370 The ILANA dissemination strategy will be formulated in conjunction with the SHARE Collaborative
371 Community Advisory Board and the study peer researcher to maximise the impact of this work on
372 clinical care and policy. This strategy will draw upon and leverage existing resources within the
373 participating organisations, such as their academic infrastructure, professional relationships and
374 community networks. Results will be disseminated in a range of innovative and engaging ways, using
375 study-specific Twitter and Instagram accounts and a study website, which allow active engagement with
376 people living with HIV , HCPs, the academic community and the wider public.

377 **Discussion**

378 Three seminal registrational trials demonstrate the clinical evidence of safety, effectiveness, tolerability
379 of LAIs ARVs ^(6, 7, 21, 22). However, there is little published ‘real-world’ evidence and no published studies
380 which focus on delivery in both the community and clinic settings, and none that focus on inclusion of
381 women and racially-minoritised people. ⁽²³⁾ Implementation science can reveal barriers, challenges,
382 opportunities for real-world uptake and scale up of innovation, helping to bridge the gap between
383 research theory and clinical practice. Our study will therefore contribute to translating knowledge by
384 exploring patients’ and providers’ experiences and perceptions of LAIs ARVs to support implementation
385 in pragmatic, real-world, settings in the clinic and community.

386 Although globally, 52% of people living with HIV are women, women, racially-minoritised and older
387 people are chronically under-represented in HIV clinical trials ^(12, 13) . A proactive recruitment cap in this

388 study will ensure that we go beyond 'lip-service' and hold researchers to account when designing trials,
389 including engaging with a peer researcher from the outset. Engaging actively with community
390 organisations will support wider awareness of this implementation trial and improve the chances of LAIs
391 benefitting those who might need it the most to support their adherence ⁽²⁴⁾.

392 The reasons for minority underrepresentation in clinical research are varied and complex, hence
393 longitudinal multi-phase qualitative research methods will be deployed to understand potential barriers
394 for women and racially-minoritised people living with HIV . Engagement in care can be affected by
395 unequal power dynamics between the healthcare provider and service-user, and there is a lack of
396 research on inequities in implementation outcomes. Using an equity lens as the ILANA study will help
397 identify and understand the specific and multiple dimensions affecting healthcare and medication
398 engagement ⁽²⁵⁾.

399 For example, research with Black-African communities in the UK found that patients' concerns,
400 influenced to varying degrees by migrant status in the UK, were important yet unappreciated factors
401 shaping treatment adherence ⁽²⁶⁾. The ILANA study explores participants' perceptions and barriers such
402 as social and economic hardship ⁽²⁷⁾ which affect access to care, physical and mental health, and quality
403 of life ⁽²⁸⁾.

404 Exploring the use of alternative settings for injection, including community-based settings to deliver
405 CAB+RPV-LA, has the potential to expand options for access whilst also potentially mitigating against the
406 human resource requirements of delivering injections and improving capacity. Previous research has
407 shown that community-based delivery of ART increases viral suppression among people living with HIV
408 ⁽²⁹⁾. Many people living with HIV report fear of encountering stigma when attending HIV clinics, which
409 can affect engagement with care. Therefore, receiving care in a community setting may provide
410 additional and preferable choices and the possibility of receiving treatment in a less medicalised setting

411 ⁽³⁰⁾. Shared decision-making between patient and healthcare providers builds trust and strengthen
412 partnerships ⁽³¹⁾ which can support optimum transition from oral ART to injectable ART.

413 Education about LAIs for healthcare providers and people living with HIV is vital to the success of
414 implementation. To facilitate increased availability of long-acting injectable options and ensure health
415 equity for the UK and at global scale, it is vital to adapt healthcare systems and facilities and to develop
416 pathways that work for a diverse range of people.

417 Finally, the NO-LANA sub-study was designed to capture the reasons for non-participation in ILANA,
418 both as a form of reflexive practice and as an exemplar of factors that might drive reluctance to take
419 part in research even when individuals are interested in the intervention on offer. Findings from NO-
420 LANA will be applicable beyond the ILANA study through theoretical generalisation, illuminate barriers
421 to research participation and gather patient-driven suggestions on how to address these.

422 **Limitations**

423 The ILANA trial is primarily based in the NHS setting and in the Global North. The findings may not be
424 reproducible in countries of the Global South where there remains an urgent need for LAIs but where
425 health systems, epidemiological landscape and broader socio-economic contexts differ substantially
426 from those in England.

427 Moreover, all ILANA sites are in large and inner-city settings, which leaves a data gap regarding
428 implementation of LAIs in smaller and rural settings. The small sample size and specific targets for
429 women and racially-minoritised groups aims at being representative of the HIV epidemic in the UK, but
430 may not be representative of the population of patients choosing the injectable option.

431 Finally, the ILANA participants will have a history of good adherence which is needed to be eligible for
432 LAIs in the NHS, which may mean the evidence of the impact of injectables on their adherence might
433 prove less generalisable to wider populations living with HIV in the UK.


434 **Conclusion**

435 Long-acting ART has the potential to move the field closer to the goal of offering ART that more people
436 can accept and adhere to. With its novel study design, the ILANA trial aims to fulfill a significant
437 knowledge gap about optimal implementation strategies with close attention to patient experience,
438 real-world practice in health systems, and alternative access options for marginalized and
439 underrepresented populations. Only by addressing these issues throughout our innovation efforts we
440 can reduce health inequity for people living with HIV.

441

442 **Figures**

ILANA STUDY - DESIGN



443

444

Figure 1 - ILANA Study Design

445 Tables

446 **Table 1**

447 Table 1: Outcome measures

Participant outcomes
<p>Primary outcome</p> <ul style="list-style-type: none"> The primary outcome measure is the proportion of participants that agree or completely agree (average score of 4 or higher) on the Feasibility of Intervention Measure (FIM) at 12 months in relation to the injection.
<p>Secondary outcomes</p> <ul style="list-style-type: none"> The proportion of participants that agree or completely agree (average score of 4 or higher) on the FIM at 4 months in relation to the injection. The proportion of participants that agree or completely agree (average score of 4 or higher) on the FIM at 12 months in relation to the alternative community-based location. The proportion of participants that agree or completely agree (average score of 4 or higher) on the FIM at 4 months in relation to the alternative community-based location. Proportion participants that agree/completely agree (average score 4 or higher) on the

<p>Acceptability of Intervention Measure (AIM) at 4 and 12 months in relation to the injection</p> <ul style="list-style-type: none">• Proportion participants that agree/completely agree (average score 4 or higher) on the AIM at 4 and 12 months in relation to the alternative community-based location• Change from baseline in HIV Treatment Satisfaction Questionnaire (HIVTSQs-12) at 4 and 12 months• Descriptive summaries of the tolerability and acceptance of injections as measured by the acceptability/convenience of injections questionnaire at 4 and 12 months• Change from baseline in Intervention Appropriateness Measure (IAM) score at 4 and 12 months in relation to the injection• Change from baseline in IAM score at 4 and 12 months in relation to the alternative community-based location• Descriptive summaries of the barriers and facilitators to implementation of CAB and RPV LA as measured by the questionnaires on appointment scheduling, preferences for information, appointment reminders, appointment times and locations and stigma/fad concepts measured at 4 and 12 months• Descriptive summaries for participant preferences for injection settings as measured by the questionnaires on differentiating care settings, treatment location preferences and time spent in/getting to clinic at 4 and 12 months
<p>Adherence outcomes</p>
<ul style="list-style-type: none">• Proportion participants who receive all injections on the target date up to 4 months from baseline• Proportion participants who receive all injections on the target date up to 12 months from baseline• Proportion participants who receive all injections within ± 7 days of target date up to 4 months from baseline• Proportion participants who receive all injections within ± 7 days of target date up to 12 months from baseline• Proportion participants who receive all injections within ± 14 days of target date up to 4 months from baseline• Proportion participants who receive all injections within ± 14 days of target date up to 12 months from baseline• Proportion of participant who missed at least one injection within 4 months and 12 months from baseline.• Proportion participants who received oral bridging for all missed injections within 4 months and 12 months from baseline.• Number of injections given outside 7-day window within 4 months and 12 months from baseline.• Proportion of injections given outside 7 days where oral bridging was used within 4 months and 12 months from baseline.• Number of participants with injections given outside 7-day window• Proportion of participants with injections given outside 7 days where oral bridging was used

Tertiary outcomes (relating to safety and clinical efficacy)
<ul style="list-style-type: none">• Proportion of participant with at least one and number of serious adverse event (SAE)• Proportion of participants with at least one and number of adverse drug reactions (ADR) (excluding injection site reactions)• Number of pregnancies and pregnancy outcomes• Proportion of participants with at least one device failure and number of device failures• Proportion of participants who fail to progress to injections/discontinuation during oral lead-in• Proportion of participants who discontinue CAB and RPV LA• Proportion who discontinue CAB and RPV LA due to SAE• Proportion who discontinue CAB and RPV LA due to an adverse drug reaction (excluding injection site reactions)• Proportion who discontinue CAB and RPV LA due to injection-related reason (injection site reactions or inconvenience)• Proportion of participants within each of the following categories of HIV viral load: (VL) \geq 200c/ml, (VL) \geq 50c/ml <200c/mL or (VL) < 50c/ml
Provider outcomes: Care provider and nurse participant outcomes
<ul style="list-style-type: none">• The proportion of participants that agree or completely agree (average score of 4 or higher) on the Feasibility of Intervention Measure (FIM) at 4 and 12 months.• Proportion of participants that agree/completely agree (average score 4 or higher) on the Acceptability of Intervention Measure (AIM) at 4 and 12 months• Descriptive summaries of the barriers and facilitators to implementation of CAB and RPV LA at 4 and 12 months• The proportion of participants that used the implementation Blueprint at 4 and 12 months
Provider outcomes: Community site representative outcomes
<ul style="list-style-type: none">• The proportion of participants that agree or completely agree (average score of 4 or higher) on the Feasibility of Intervention Measure (FIM) at 8 and 12 months.• Proportion participants that agree/completely agree (average score 4 or higher) on the Acceptability of Intervention Measure (AIM) at 8 and 12 months

448

449 **Supplementary Appendix**



ILANA SAP.pdf

450

451 **References**

- 452 1. Drake AL, Wagner A, Richardson B, John-Stewart G. Incident HIV during Pregnancy and
453 Postpartum and Risk of Mother-to-Child HIV Transmission: A Systematic Review and Meta-Analysis.
454 PLOS MEDICINE. 2014;11(2).
- 455 2. Ferrand RA, Corbett EL, Wood R, Hargrove J, Ndhlovu CE, Cowan FM, et al. AIDS among older
456 children and adolescents in Southern Africa: projecting the time course and magnitude of the epidemic.
457 AIDS. 2009;23(15):2039-46.
- 458 3. UN/WHO. UNAIDS data 2018 - UN Joint Programme on HIV/AIDS (UNAIDS) 2018 [Available from:
459 <http://www.unaids.org/en/resources/documents/2018/unaids-data-2018>.
- 460 4. Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, et al. Benefits and risks of
461 rapid initiation of antiretroviral therapy. AIDS. 2018;32(1).
- 462 5. Swindells S, Lutz T, Van Zyl L, Porteiro N, Stoll M, Mitha E, et al. Week 96 extension results of a
463 Phase 3 study evaluating long-acting cabotegravir with rilpivirine for HIV-1 treatment. AIDS. 2022;36(2).
- 464 6. Orkin C, Oka S, Philibert P, Brinson C, Bassa AC, Gusev D, et al. Long-acting cabotegravir +
465 rilpivirine for HIV treatment: FLAIR week 96 results. HIV Medicine. 2020;21(SUPPL 4):14.
- 466 7. Orkin C, Oka S, Philibert P, Brinson C, Bassa A, Gusev D, et al. Long-acting cabotegravir plus
467 rilpivirine for treatment in adults with HIV-1 infection: 96-week results of the randomised, open-label,
468 phase 3 FLAIR study. LANCET HIV. 2021;8(4):e185-e96.
- 469 8. Chounta V, Overton ET, Mills A, Swindells S, Benn PD, Vanveggel S, et al. Patient-Reported
470 Outcomes Through 1 Year of an HIV-1 Clinical Trial Evaluating Long-Acting Cabotegravir and Rilpivirine
471 Administered Every 4 or 8 Weeks (ATLAS-2M). Patient. 2021;14(6):849-62.
- 472 9. Flamm J, Garris C, D'Amico R, Dalessandro M, McHorney CA, Mansukhani SG, et al. PB4 Patient
473 Perspectives on Implementation of a Long-Acting Injectable Antiretroviral Therapy Regimen in HIV US
474 Healthcare Settings: Final Month 12 Results from the CUSTOMIZE Study. Value in Health. 2021;24:S13.
- 475 10. Havlir D, Gandhi M. Implementation challenges for long-acting antivirals as treatment. Current
476 Opinion in HIV and AIDS. 2015;10(4).
- 477 11. Hedge B, Devan K, Catalan J, Cheshire A, Ridge D. HIV-related stigma in the UK then and now: to
478 what extent are we on track to eliminate stigma? A qualitative investigation. BMC Public Health.
479 2021;21(1):1022.
- 480 12. Castillo-Mancilla JR, Cohn SE, Krishnan S, Cespedes M, Floris-Moore M, Schulte G, et al.
481 Minorities remain underrepresented in HIV/AIDS research despite access to clinical trials. HIV clinical
482 trials. 2014;15(1):14-26.
- 483 13. Curno MJ, Rossi S, Hodges-Mameletzis I, Johnston R, Price MA, Heidari S. A Systematic Review of
484 the Inclusion (or Exclusion) of Women in HIV Research: From Clinical Studies of Antiretrovirals and
485 Vaccines to Cure Strategies. JAIDS Journal of Acquired Immune Deficiency Syndromes. 2016;71(2).
- 486 14. Dhairyawan R, Okhai H, Hill T, Sabin CA. Differences in HIV clinical outcomes amongst
487 heterosexuals in the United Kingdom by ethnicity. AIDS. 2021;35(11).
- 488 15. UNAIDS. 2020 Global AIDS update—seizing the moment—tackling entrenched inequalities to
489 end epidemics.
- 490 16. O'Halloran C, Sun S, Nash S, Brown A, Croxford S, N C. *HIV in the United Kingdom: Towards Zero*
491 *2030. 2019 report* . London: Public Health England; 2019.
- 492 17. Orkin C, Apea V. International Women's Day—how can I help? The Lancet HIV. 2022;9(4):e228-
493 e9.
- 494 18. Devotta K, Woodhall-Melnik J, Pedersen C, Wendaferew A, Dowbor TP, Guilcher SJT, et al.
495 Enriching qualitative research by engaging peer interviewers: a case study. Qualitative Research.
496 2016;16(6):661-80.

- 497 19. ICMJE. Defining the Role of Authors and Contributors 2021 [Available from:
498 [http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-
500 authors-and-contributors.html](http://www.icmje.org/recommendations/browse/roles-and-responsibilities/defining-the-role-of-
499 authors-and-contributors.html).
501 20. Weiner BJ, Lewis CC, Stanick C, Powell BJ, Dorsey CN, Clary AS, et al. Psychometric assessment of
502 three newly developed implementation outcome measures. *Implementation Science*. 2017;12(1):108.
503 21. Orkin C, Arasteh K, Hernandez-Mora MG, Pokrovsky V, Overton ET, Girard P-M, et al. Long-acting
504 cabotegravir + rilpivirine for HIV maintenance: Flair week 48 results. *Topics in Antiviral Medicine*.
505 2019;27(SUPPL 1):52s-3s.
506 22. Orkin C, Arasteh K, Górgolas Hernández-Mora M, Pokrovsky V, Overton ET, Girard P-M, et al.
507 Long-Acting Cabotegravir and Rilpivirine after Oral Induction for HIV-1 Infection. *New England Journal of
508 Medicine*. 2020;382(12):1124-35.
509 23. Schlechter CR, Del Fiol G, Lam CY, Fernandez ME, Greene T, Yack M, et al. Application of
510 community – engaged dissemination and implementation science to improve health equity. *Preventive
511 Medicine Reports*. 2021;24:101620.
512 24. Glandon D, Paina L, Alonge O, Peters DH, Bennett S. 10 Best resources for community
513 engagement in implementation research. *Health Policy and Planning*. 2017;32(10):1457-65.
514 25. Baumann AA, Cabassa LJ. Reframing implementation science to address inequities in healthcare
515 delivery. *BMC Health Services Research*. 2020;20(1):190.
516 26. Thomas F, Aggleton P, Anderson J. ‘Experts’, ‘partners’ and ‘fools’: Exploring agency in HIV
517 treatment seeking among African migrants in London. *Social Science & Medicine*. 2010;70(5):736-43.
518 27. Ibrahim F, Anderson J, Bukutu C, Elford J. Social and economic hardship among people living
519 with HIV in London. *HIV medicine*. 2008;9:616-24.
520 28. Solomon D, Tariq S, Alldis J, Burns F, Gilson R, Sabin C, et al. Ethnic inequalities in mental health
521 and socioeconomic status among older women living with HIV: results from the PRIME Study. *Sexually
522 Transmitted Infections*. 2022;98(2):128.
523 29. Barnabas RV, Szpiro AA, van Rooyen H, Asimwe S, Pillay D, Ware NC, et al. Community-based
524 antiretroviral therapy versus standard clinic-based services for HIV in South Africa and Uganda (DO ART):
525 a randomised trial. *The Lancet Global Health*. 2020;8(10):e1305-e15.
526 30. Zheng C, Wang W, Young SD. Identifying HIV-related digital social influencers using an iterative
527 deep learning approach. *AIDS*. 2021;35:S85-S9.
528 31. Kanazawa JT, Saberi P, Saucedo JA, Dubé K. The LAIs Are Coming! Implementation Science
529 Considerations for Long-Acting Injectable Antiretroviral Therapy in the United States: A Scoping Review.
AIDS Research and Human Retroviruses. 2020;37(2):75-88.

530

ILANA STUDY - DESIGN

